Cyp11a1 inhibitor for use in the treatment of prostate cancer
OwnerTarja IKONEN, Annamari VUORELAinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of an activating AR gene alteration as a biomarker for identifying prostate cancer patients who have a higher probability to be responsive to the treatment with a CYP11A1 inhibitor. The invention also relates to a method for treating prostate cancer comprising a) obtaining or having obtained a sample from the patient; b) assaying or having assayed a sample to determine whether the patient has an activating AR gene alteration and c) if the patient has an activating AR gene alteration, treating the patient with a therapeutically effective amount of a CYP11A1 inhibitor.
Claims50
A method for the treatment of prostate cancer in a patient having an activating androgen receptor (AR) gene alteration comprising administration to said patient a therapeutically effective amount of a CYP11A1 inhibitor.
A method for treating prostate cancer in a patient comprising
- a) obtaining or having obtained a sample from the patient;
- b) assaying or having assayed the sample to determine whether the patient has an activating AR gene alteration;
- and
- c) if the patient has an activating AR gene alteration, treating the patient with a therapeutically effective amount of a CYP11A1 inhibitor.
A method of selecting a patient suffering from prostate cancer for the treatment with a CYP11A1 inhibitor comprising
- a) assaying or having assayed the sample to determine whether the patient has an activating AR gene alteration;
- and
- b) if the patient has an activating AR-LBD gene alteration, selecting the patient for the treatment with a CYP11A1 inhibitor.
A method for identifying a patient suffering from prostate cancer who is more likely to respond to a treatment comprising a CYP11A1 inhibitor, the method comprising assaying or having assayed a sample obtained from the patient to determine whether the patient has an activating AR gene alteration, wherein such alteration identifies the patient as being more likely to respond to the treatment.
42-45. (canceled)
Dependencies are inferred from the claim text.